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Abstract
Background: We performed a case–control study to estimate vaccine effectiveness (VE) for prevention of
hospitalization due to pandemic influenza A(H1N1)pdm09 (pH1N1) and to identify risk factors for pH1N1 and acute
respiratory infection (ARI) in 10 hospitals in Berlin from December 2009 to April 2010.
Methods: Cases were patients aged 18–65 years with onset of ARI ≤10 days before admission testing positive for
pH1N1 by PCR performed on nasal and throat swabs or by serological testing. Cases were compared to (1) matched
hospital controls with acute surgical, traumatological or other diagnoses matched on age, sex and vaccination
probability, and (2) ARI patients testing negative for pH1N1. Additionally, ARI cases were compared to matched
hospital controls. A standardized interview and chart review elicited demographic and clinical data as well as
potential risk factors for pH1N1/ARI. VE was estimated by 1-(Odds ratio) for pH1N1-vaccination ≥10 days before
symptom onset using exact logistic regression analysis.
Results: Of 177 ARI cases recruited, 27 tested pH1N1 positive. A monovalent AS03-adjuvanted pH1N1 vaccine was
the only pandemic vaccine type identified among cases and controls (vaccination coverage in control group 1 and
2: 15% and 5.9%). The only breakthrough infections were observed in 2 of 3 vaccinated HIV positive pH1N1 patients.
After exclusion of HIV positive participants, VE was 96% (95%CI: 26-100%) in the matched multivariate analysis and
46% (95%CI: -376-100%) in the test-negative analysis. Exposure to children in the household was independently
associated with hospitalization for pH1N1 and ARI.
Conclusions: Though limited by low vaccination coverage and number of pH1N1 cases, our results suggest a
protective effect of the AS03-adjuvanted pH1N1 vaccine for the prevention of pH1N1 hospitalization. The use of
hospital but not test-negative controls showed a statistically protective effect of pH1N1-vaccination and permitted
the integrated assessment of risk factors for pH1N1-infection. To increase statistical power and to permit stratified
analyses (e.g. VE for specific risk groups), the authors suggest pooling of future studies assessing effectiveness of
influenza vaccines for prevention of severe disease from different centres.
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Background
In June 2009 the World Health Organization (WHO)
declared a global pandemic after the emergence of a novel
influenza A(H1N1) virus initially in Mexico and the USA
that rapidly spread world-wide [1,2]. In Germany, vaccin-
ation against pandemic influenza A(H1N1)pdm09 (from
here on referred to as pH1N1) was initiated 2 weeks into
the main pandemic wave in calendar week 44 [3] with Pan-
demrixW, a monovalent AS03-adjuvanted pH1N1-vaccine
produced by GlaxoSmithKline. A non-adjuvanted vaccine
was introduced 7 weeks later, but was restricted to preg-
nant women. Preliminary results of a randomized clinical
trial of the AS03-adjuvanted vaccine containing 5.25 μg
haemagglutinin showed seroconversion and seroprotection
rates >96% after one dose [4]. Later results confirmed ex-
cellent immunogenicity of the widely implemented 3.75 μg
dose formulation in adults up to age 85 years [5].
While immunogenicity data remain the basis for licen-
sure of influenza vaccines, correlation with clinical protec-
tion against pandemic influenza after pH1N1-vaccination
was not known. Therefore, we launched a hospital-based
case-control study in Berlin to estimate the effectiveness of
pH1N1-vaccination for prevention of hospitalization due
to pH1N1. Secondary objectives were to determine the ef-
fect of previous vaccination with seasonal influenza vac-
cine on the risk of hospitalization with pH1N1, and to
identify risk factors for hospitalization with pH1N1 or
acute respiratory infection (ARI).
Methods
Study design and setting
We performed a prospective hospital-based case–control
study in nine community hospitals comprising the
Vivantes Network for Health located in seven of the 12
Berlin districts and one of the Charité University hospitals
located in an eighth district, together serving approxi-
mately one third of the Berlin population of 3.8 million
inhabitants from week 50, 2009 to week 14, 2010.
Study population
ARI cases were defined as patients aged 18–65 years ad-
mitted to the participating hospitals with symptom onset
≤10 days prior to admission and the following clinical
criteria for ARI: [(fever >38.0°C or other systemic symp-
toms such as chills, headache, myalgia/arthralgia) AND
(cough or sore throat)] OR [influenza-like illness, influ-
enza, acute bronchitis or pneumonia suspected/diag-
nosed by a physician]. Older patients were not recruited,
since a low pH1N1-incidence was expected among them
based on the age distribution of cases notified in Ger-
many at the time the study was planned (<1% of cases
aged >60 years [6]). Newly admitted ARI patients were
identified by daily screening of the hospital information
system. We excluded patients unable to give informed
consent or to communicate adequately, those with an
absolute contra-indication for influenza vaccination (his-
tory of anaphylaxis from vaccine components) or with a
history of prior laboratory-confirmed pH1N1-infection.
As one of the centres specialized in the treatment of
HIV patients, we expected to recruit a disproportionately
high number of HIV-positive participants. Rather than
exclude HIV patients from recruitment, we decided to
exclude them from the primary VE-analysis, but to
undertake a separate VE analysis among HIV patients if
a sufficient number could be recruited..
Newly admitted patients with either acute surgical, trau-
matological, urological, nephrological, gynaecological or
medical diagnoses or with minor elective surgical proce-
dures were also documented daily as potential controls. For
each case patient, a control was then randomly selected and
recruited according to the following matching criteria: date
of admission (+/− 10 days), age (+/− 10 years), sex and vac-
cination probability. Medical personnel, persons with
underlying chronic illness, pregnant women and police/fire
workers were defined as having a high vaccination probabil-
ity based on the official vaccination recommendations that
prioritized these groups for receipt of pH1N1-vaccine [7,8].
Exclusion criteria for controls were as described for cases
along with a history of a respiratory illness with sudden
onset and fever and cough and either myalgia, arthralgia or
headache since October 1, 2009, OR serological evidence of
previous pH1N1-infection.
Sample size calculation
We assumed a moderate to high vaccine effectiveness (VE)
based on the literature on seasonal influenza vaccination
in healthy adults with a good vaccine/circulating virus
match [9,10]. We expected low to moderate vaccination
coverage in view of controversial public discussion on pan-
demic vaccination in Germany at the time [11]. Thus, at a
power of 80% and with 2 controls per case, we estimated
we would need to recruit 85 (VE=90%; vaccination cover-
age= 30%) to 249 pH1N1 positive cases (VE=60%; vaccin-
ation coverage= 10%).
Data collection
A standardized interview elicited demographic data, illness
onset, clinical symptoms, vaccination history and risk fac-
tors for respiratory infections or potential confounders
such as demographic factors, underlying illness, smoking,
body mass index (BMI), functional health status, contact
with children, use of public transport and car ownership.
When possible, the vaccination history was obtained from
the vaccination record; if unavailable, it was requested
from the family doctor. If neither approach was possible,
we documented the data from the patient’s memory; how-
ever, if a reportedly vaccinated patient was unable to recall
at least the month/year of pH1N1 or seasonal 2009/2010
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influenza vaccination or the year of pneumococcal vaccin-
ation, vaccination status was considered unknown. For
seasonal 2007/2008 or 2008/2009 vaccination, recall of the
year of vaccination was considered sufficient. The patient’s
chart was reviewed after discharge to retrieve clinical and
laboratory data on illness severity/progression, underlying
illness, as well as radiological and microbiological findings.
The patient’s own or a report in the medical record was
considered sufficient evidence for underlying medical con-
ditions. We defined chronic lung disease as at least one of
chronic obstructive lung disease (COPD), asthma, chronic
bronchitis or regular use of bronchodilators, and underlying
cardiovascular disease as a history of heart disease, stroke
or use of antiplatelet agents, but not isolated hypertension.
“Frailty” was defined as requiring help with personal hy-
giene, with walking or with meals. Regular use of public
transport was defined as use at least 3 times per week. The
status of either having or being eligible for private health in-
surance was used as a proxy for higher income. We defined
high educational status as having completed at least grade
10, required for further vocational training in Germany.
Laboratory methods
Nasal and throat swabs (Mastaswab; MAST Diagnostica,
Reinfeld, Germany) were collected from consenting ARI
cases, stored refrigerated and shipped to the National Refer-
ence Centre for Influenza (NIC) within 1–4 days. If patients
were intubated, tracheal secretions (n=1) or bronchioalveo-
lar lavage fluid (n=6) were tested. Samples were washed
out in 1.5 ml cell culture medium and combined. RNA was
extracted from 300 μl of the pooled sample using the
MagAttract Viral RNA 48 Kit (Qiagen) and eluted in 80 μl
elution buffer. cDNA was synthesized using 25 μl of RNA
and 200U M-MLV Reverse Transcriptase (Invitrogen) in a
total reaction volume of 40 μl. Real-time polymerase chain
reaction (PCR) was performed as described previously, tar-
geting the M gene for universal detection of influenza A
viruses as well as the HA and NA genes for further subtyp-
ing including the specific detection of pH1N1 viruses [12].
Identification and differentiation of influenza B viruses were
performed according to Biere et al. [13].
A serum sample was requested from ARI cases and hos-
pital controls upon recruitment, and from cases again 2–
4 weeks later. Haemagglutination inhibition (HI) was per-
formed at NIC to measure pH1N1-specific antibodies by as
described previously [14], using the reference strain A/Cali-
fornia/7/2009. An international pH1N1 serum standard
(HI-titre: 1:183) provided by the National Institute for Bio-
logical Standards and Control, London, UK, was included
in addition to negative and positive human control sera. A
comparable titre of 1:160 was obtained for the standard in
different runs. HI titres were expressed as the reciprocal of
the last serum dilution preventing haemagglutination. The
minimum detection limit was 1:10.
Data analysis
Patients were considered pH1N1-positive if the nasopha-
ryngeal swab was PCR-positive or if pH1N1 serum anti-
body-titres increased either from 0 to ≥40 or at least 4-fold
in the acute and convalescent sera. Patients were consid-
ered pH1N1-negative if a nasopharyngeal swab taken
within 7 days of symptom onset was PCR-negative.
Patients with PCR-negative swabs taken >7 days after
symptom onset were considered pH1N1-negative only if
the pH1N1 antibody titre in both serum samples was 0, or
- if pH1N1-vaccinated - if the titre remained stable (≤ 2-
fold increase) or decreased. The cut-off at day 7 was
chosen based on several studies investigating shedding of
influenza viruses that showed a low probability of PCR-
positivity after this time [15-17], although two studies in
elderly hospitalized patients showed >50% of patients
were still shedding virus 7 days after symptom onset
[18,19]. We performed a sensitivity analysis using a cut-off
of 4 days. Recruited controls with serological evidence of
previous pH1N1-infection (HI titer≥ 40) were excluded
from the analyses.
The study period was divided into periods 1 (week 48,
2009 to week 2, 2010) with high-level, and 2 (week 3 to
week 17, 2010) with low-level pH1N1 circulation [20].
Patients were excluded from VE analysis if they were
HIV-positive or if their pH1N1-status or vaccination status
could not be determined (see Figure 1). Since studies
showed high VE [21] and immunogenicity [22] for the
AS03-adjuvanted pH1N1-vaccine already 7 days after vac-
cination, as well as similar VE 7–10 days after vaccination
as after the more conventional 14 days [23-27], we consid-
ered ARI patients and hospital controls pH1N1-vaccinated
if they received ≥1 dose of pandemic vaccine ≥10 days
prior to symptom onset and admission, respectively. We
performed sensitivity analyses using a 14-day cut-off.
VE, calculated as [(1-Odds ratio (OR)) x 100%] and risk
factors for hospitalization with pH1N1 were determined in
the following comparisons: (1) pH1N1-positive ARI cases
compared to matched hospital controls using exact logistic
regression to calculate matched odds ratios (MOR) with
the group function in STATA (Version 11.0, STATA
Corp.); (2) pH1N1-positive ARI cases compared to
pH1N1-negative ARI-patients as controls using multivari-
ate exact logistic regression in SAS (version 0.2, SAS Insti-
tute Inc.).
To identify risk factors for hospitalization with ARI, ARI
cases were compared to matched hospital controls using
conditional logistic regression in STATA. Proportions were
compared using the chi-square test.
Informed consent and ethical approval
All participants provided written informed consent. The
study was approved by the local Ethics Committee of Charité
University Medicine Berlin.




Of 299 identified ARI patients 177 (59%) consented to par-
ticipate in the study. Recruited and non-recruited patients
did not differ with respect to age and sex distribution, nor
regarding the frequency of key symptoms such as fever,
cough/sore throat or dyspnoea. The proportion of ARI
cases testing pH1N1-positive was higher in period 1 (22/
63, 35%) than period 2 (5/114; 4%; p< 0.001). Among ARI
patients aged <55 years, 19.2% tested pH1N1-positive ver-
sus 7.4% among 55–65 year-olds (p= 0.05). Figure 1
describes the ARI cases according to their laboratory
results and pH1N1-vaccination status; 19 HIV-positive
ARI cases (8 vaccinated) were excluded from VE analyses.
Two ARI cases (including one pH1N1-positive) were
pregnant.
We recruited 308 hospital controls (Figure 2), of which
4 HIV patients (3 pH1N1-vaccinated) were excluded. Of
304 remaining controls, 28 (9.8%, all unvaccinated) were
excluded because of a pH1N1-specific HI titre ≥1:40. Of
the remaining 276 controls, 55% were acute surgical
patients, 35% had planned surgical interventions and
10% other acute diagnoses.
Vaccination status
The only pH1N1-vaccination breakthrough infections
occurred in 2/3 pH1N1-positive HIV-patients; none of
the remaining 24 pH1N1-positive cases were pH1N1-
vaccinated. Overall, 11/158 (7.0%) recruited ARI cases
and 18/276 (6.5%) hospital controls were pH1N1-vacci-
nated (Figures 1 and 2), compared to 30.4% and 22.2%
vaccinated with seasonal 2009/2010 influenza vaccine,
respectively. pH1N1-vaccination coverage was similar in
study participants with high and low vaccination prob-
ability (7.1% (20/281) versus 5.0% (9/179), p = 0.37). All
vaccinated participants received one dose of PandemrixW
12–120 days before symptom onset (ARI cases) or hos-
pital admission (hospital controls) with the exception of
1 hospital control with 2 doses 34 and 13 days before
admission.
177 recruited ARI cases
19 HIV-positive excluded 
(3 pH1N1-positive,  12 
negative, 4 unclear)
158 ARI cases remaining
24 pH1N1 positive 119  pH1N1 negative15 pH1N1-status unclear
• 9 PCR + serology pos 
• 4 positive serology only (1 PCR 
negative, 3 swabbed late*)
• 11 pos PCR only (3 
seronegative, 1 serology 
unclear**, 7 no serum
• 8 PCR negative but swabbed 
late, no serology
• 7 PCR negative, swabbed 
late, serology results did not 
clearly rule out acute 
infection***
• 103 PCR negative
• 38 seronegative
• 18 serology unclear
• 47 no serum
• 16 seronegative, PCR negative but 
swabbed late*
*Swabbed >7 days after symptom onset **pH1N1 titre 1:80 on day 10 and day 35 *** 1st serum sample taken > 7 days after 
symptom onset (8-13 days), 5  had identical titre in 1st and 2nd sample (range 1:20-1:320); 2 had 2-fold titre increases from 1:20-
1:40 (interval b/w 1st and 2nd serum=7 days) and 1:40 to 1:80) **** pH1N1-titer in first serum >0, but no four-fold increase (n=5), 
titre increase from 0 to 1:10 (n=3) ‡Swabbed on days 8 (2), 10 (1) and 13 (1)
7  pH1N1 
vaccinated














Figure 1 Recruited ARI patients according to pH1N1 diagnosis and pH1N1-vaccination status.
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Both pH1N1-vaccination and 2009/2010 seasonal influ-
enza vaccination status were documented in the vaccin-
ation record or confirmed by the vaccinating physician in
a high proportion of vaccinated (90%), but in a low pro-
portion of unvaccinated (25%) study participants and this
was similar in cases and controls included in the VE ana-
lyses (Table 1).
Comparison of pH1N1-positive cases with matched
hospital controls
Because the only control of one case had to be excluded
due to seropositivity, 23 pH1N1-positive cases (mean age:
41.5 ± 14.1 years, 74% male) were compared to 40 matched
controls (41.5± 12.7 years, 73% male); 6 were paired with
1 control and 17 with 2 controls. Of the 40 controls, 6
(15.0%) were pH1N1-vaccinated.
As none of the pH1N1-positive cases was vaccinated
against pH1N1, the crude MOR and VE estimates were
0 and 100%, respectively. The univariate median un-
biased estimate of the MOR calculated using exact logis-
tic regression analysis for pH1N1-vaccination was 0.19
(95%CI: 0–1.54, p = 0.13), corresponding to a VE of 81%
(95% CI: -54%-100%). A number of other factors were
associated with pH1N1-infection in exact logistic regres-
sion analysis (Table 2), although only exposure to chil-
dren in the household (MOR: 4.3, 95% CI: 1.0-26.0,
p = 0.04) and ≥1 hospitalization in the past year (MOR=
0.2, 95% CI: 0–0.7, p = 0.01) reached statistical signifi-
cance. A positive association with pH1N1 illness that
approached statistical significance was observed for
COPD (p = 0.06), immunosuppression (p = 0.07), BMI
(p = 0.06), car ownership (p=0.06) and a negative associ-
ation for having been offered pandemic vaccine by one’s
employer (p = 0.07) and use of public transport (p = 0.06,
see Table 2). None of the variables associated with
pH1N1 illness was significantly associated with pH1N1-
vaccination in this data set (results not shown). However,
among controls (but not cases), owning a car was posi-
tively (p = 0.05) and frequent use of public transport in-
versely (p = 0.06) associated with children in the
household, possibly explaining the positive association
between car ownership (p = 0.06) and pH1N1 illness.






•13 seropositive (all 
pH1N1 titre r 1:80)
•2 no serum sample




•15 pH1N1 titre 1:10 
•25 pH1N1 titre 1:20
•22 no serum sample
* Vaccination documented in vaccination record (2) or by family doctor (1)




Figure 2 Recruited hospital controls according to pH1N1 diagnosis and pH1N1-vaccination status.
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There was no association between pH1N1 illness and
seasonal influenza vaccination, smoking, educational sta-
tus or health insurance status (Table 2).
In multivariate analysis, the MOR for pH1N1-vaccination
was 0.04 (95%CI: 0–0.74), corresponding to a VE of 96%
(95%CI: 26-100%). In the final model, pH1N1-vaccination
remained predictive of pH1N1 illness, together with the
variables “contact to children in the household” (OR=9.2,
95%CI: 1.1–440.0, p=0.03) and “≥1 hospital admission in
previous year” (OR=0.1, 95%CI: 0–0.6, p=0.01). The OR
for additional variables added to the model did not reach
statistical significance and had minimal further influence on
the effect of these covariates. If only persons vaccinated ≤14
rather than ≤10 days prior to symptom onset (ARI cases) or
hospitalization (hospital controls) were considered to be
pH1N1-vaccinated, the estimated OR for pH1N1-vaccin-
ation changed only minimally (univariate estimate: 0.20,
95%CI: 0–1.87; multivariate estimate: 0.04, 95%CI: 0–0.69).
Comparison of pH1N1-positive cases with test-negative
controls
In the test-negative analysis, 24 pH1N1-positive ARI cases
were compared to 119 pH1N1-negative ARI cases
(Figure 1), of whom 7 (5.9%) were vaccinated, all >21 days
prior to symptom onset. pH1N1-positive cases were sig-
nificantly younger (41.6± 12.5 years) than test-negative
cases (48.1± 12.3 years, p = 0.02) and more likely to have
had symptom onset in time period 1 (83% versus 28%,
p< 0.0001). Therefore, all analyses were adjusted for age
and time period. The sex distribution (71% vs. 61% men,
p= 0.11) and the proportion of patients with a higher vac-
cination probability (67% vs. 59%, p= 0.28) were similar.
The OR for pH1N1-vaccination was 0.54 (95% CI:
0–4.76), yielding a VE of 46% (95%CI: -376%–100%). We
did not find a significant association between pH1N1 illness
and seasonal influenza vaccination, although OR estimates
for the 2008/2009 and the 2007/2008 seasonal vaccination
were non-significantly increased. Significant associations be-
tween further variables and pH1N1-positivity were not
found in this analysis (Table 2), with the exception of car
ownership (OR=3.6, 95%CI: 1.1–13.9, p=0.04). The inverse
association between pH1N1-positivity and public transport
also seen in the matched analysis approached statistical sig-
nificance (p=0.06). Among controls (but not cases), owning
a car was positively (p=0.07) and frequent use of public
transport inversely (p=0.17) associated with children in the
household, but exposure to children was similar in cases
and test-negative controls in this analysis (Table 2).
Addition of variables with an OR having p< 0.20 singly to
the exact logistic regression equation containing age, time
period and pH1N1-vaccination had minimal effect on the
OR for pH1N1-vaccination.
When using a cut-off of 4 rather than 7 days after symp-
tom onset as the interval for considering a negative PCR
result as definitively negative, the OR for pH1N1-vaccination
changed minimally (OR=0.50 (95%CI: 0–4.44), equivalent
to aVE of 50% (95%CI: -344–100%)).
Factors associated with hospitalization for ARI
After exclusion of HIV positive ARI-cases and hospital
controls, 6 ARI-cases were left without a hospital control,
and 30 hospital controls no longer had a case. Thus, 152
ARI-cases (mean age: 47.0± 12.7 years, 64% male) were
compared to 246 matched hospital controls (47.6± 12.5,
65% male); 58 cases were paired with one and 94 with 2
controls. Results of the univariate conditional logistic re-
gression analysis are shown in Table 3. In multivariate
backwards conditional logistic regression, only COPD
(OR=19.4, 95%CI: 4.4-85.8, p< 0.0001), exposure to chil-
dren in the household (OR=2.4, 95%CI: 1.3-4.5,
p =<0.007), and having had pH1N1-vaccine offered by an
employer (OR=0.4, 95%CI: 0.2-0.8, p = 0.02) remained in-
dependently and significantly associated with hospitalized
ARI. A model including these variables plus cardiovascular
disease (OR=1.8, 95%CI: 0.9-3.5, p = 0.11) and pneumo-
coccal vaccination (OR=3.2, 95%CI: 0.9-11.5, p = 0.07) had
a pseudo R2 of 0.28 (removal of the 2 latter variables led to
a poorer fit (pseudo R2 = 0.20)).
Table 1 Proportion of participants with documented vaccination status (vaccination record or family physician)









Proportion with documented vaccination status* (%)
pH1N1 positive ARI
cases (N= 24)
0/0 7/24 (29%) 6/6 (100%) 5/18 (28%)
Hospital controls matched to
pH1N1 positive cases (N=40)
6/6 (100%) 12/34 (35%) 7/9 (78%) 10/39 (33%)
pH1N1 negative ARI cases
(test negative controls, N =119)
6/7 (86%) 30/110 (27%) 31/36 (86%) 19/81 (23%)
HIV patients 9/10 (90%) 11/12 (92%) 13/14 (93%) 7/7 (100%)
*Number of participants with documented vaccination status/total number of study participants in group (%).
Hellenbrand et al. BMC Infectious Diseases 2012, 12:127 Page 6 of 12
http://www.biomedcentral.com/1471-2334/12/127
Vaccination status of HIV positive study participants
VE-analysis in subgroups with underlying illness was not
feasible due to the small number of pH1N1-positive cases,
but we examined the vaccination status of HIV positive
study participants according to pH1N1 status (Table 4). Of
16 HIV-positive ARI with a definitive pH1N1 status, 2/3
(67%) pH1N1 positive patients and 4/13 (31%) pH1N1
negative patients were pH1N1 vaccinated (pχ2=0.62). Of
the 3 HIV-positive hospitals controls with known pH1N1
vaccination status, 2 were pH1N1 vaccinated. As a group,
HIV-positive study participants had a markedly higher
pandemic (45%) as well as 2009/2010 seasonal influenza
vaccination coverage (61%) than other study participants
or the general population.
Discussion
Despite the limited power of our study, the results sug-
gest that AS03-adjuvanted pH1N1-vaccination imple-
mented in Germany during the 2009 influenza pandemic
was effective in preventing hospitalization with pH1N1
Table 2 Comparison of pH1N1-positive cases with matched hospital controls and test-negative controls, respectively:
Analysis of vaccination status, underlying illness and other potential risk factors














N % N % N % N
Pandemic influenza
vaccination 2009/10
23 0 40 15 0.2 (0–1.5) 0.13 24 0 117 6 0.5 (0–4.8) 0.62
Seasonal influenza
vaccination 2009/10
23 26 39 23 1.3 (0.2-7.5) 0.99 24 25 117 31 0.8 (0.2-2.8) 0.95
Seasonal influenza
vaccination 2008/09
23 26 40 25 1.1 (0.3-4.1) 1.0 24 25 111 19 3.4 (0.6-20.8) 0.21
Seasonal influenza
vaccination 2007/08
23 22 40 20 1.2 (0.2-7.6) 1.00 24 21 110 16 2.4 (0.4-14.9) 0.45
Pneumococcal vaccine 20 20 35 11 2.3 (0.4-15.9) 0.49 21 24 103 13 3.4 (0.6-19.5) 0.19
Pandemic vaccine offered
by employer
23 9 40 30 0.1 (0–1.1) 0.07 24 8 115 12 1.1 (0.1-6.7) 1.00
Any chronic underlying illness 23 70 40 63 1.7 (0.1-117.7) 1.0 24 67 119 66 1.5 (0.4-6.3) 0.72
Any chronic lung disease 23 43 40 23 2.2 (0.6-8.6) 0.27 24 42 118 34 2.2 (0.6-7.9) 0.25
COPD 23 22 40 3 7.9 (1.0-∞) 0.06 24 21 118 27 1.2 (0.3-5.2) 0.99
Asthma 23 26 40 15 1.8 (0.4-8.9) 0.58 24 25 118 16 1.4 (0.3-5.5) 0.77
Chronic bronchitis 23 13 40 5 3.2 (0.2-177.0) 0.61 24 13 118 17 0.9 (0.1-4.5) 1.00
Cardiovascular disease 23 39 40 28 2.6 (0.4-29.2) 0.44 24 38 119 40 1.4 (0.3-5.6) 0.84
Immunosuppression 21 14 40 0 7.7 (0.8-∞) 0.07 22 14 116 15 1.1 (0.2-5.5) 1.00
BMI ≥31 23 30 39 8 5.1 (0.9-51.2) 0.06 24 29 118 17 2.3 (0.6-9.1) 0.27
Frailty 23 4 40 3 1.4 (0–117.7) 1.00 24 4 118 9 0.4 (0.1-3.4) 0.65
≥ 1 physician visits
in past year
23 70 39 72† 1.0 (0.3-3.3) 1.00 24 67 118 73† 1.7 (0.5-6.6) 0.54
≥ 3 physician visits in past year 23 48 39 38{ 1.5 (0.4-4.9) 0.64 24 46 118 53{ 1.3 (0.4-4.2) 0.84
≥ 1 hospitalization in past year 23 17 39 49 0.2 (0–0.7) 0.01 24 17 119 32 0.4 (0.1-1.6) 0.26
Current smoker 23 61 40 53 1.3 (0.4-3.8) 0.81 24 58 119 40 1.6 (0.5-4.8) 0.53
>20 packyears vs. non-smoker 23 30 40 25 1.8 (0.4-11.1) 0.69 24 29 119 33 2.2 (0.4-14.4) 0.52
Alcohol: ≥ 1 drink/week 23 43 40 65 0.3 (0.1-1.1) 0.08 24 45 117 56 0.6 (0.2-1.8) 0.40
Children in household 23 39 40 15 4.3 (1.0-26.0) 0.04 24 38 119 36 1.0 (0.3-3.0) 1.00
Public transport (>=3x/week)
vs. none
23 30 40 58 0.2 (0–1.1) 0.06 24 29 119 45 0.3 (0.1-1.0) 0.06
Owns car 23 74 40 45 3.3 (1.0-14.3) 0.06 24 75 119 51 3.6 (1.1-13.9) 0.04
Completion of at least
Grade 10
23 68 40 77 0.6 (0.1-3.1) 0.72 24 71 117 69 1.5 (0.5-5.4) 0.66
Private health insurance 23 24 40 13 2.1 (0.2-26.2) 0.74 24 25 119 17 1.2 (0.3-4.2) 1.00
*MOR calculated with exact logistic regression. **Adjusted for time period and age.
Comparison of hospital and test-negative controls: †pχ2= 0.11 {pχ2= 0.90.
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illness in adults ≤65 years of age. In another hospital-
based case–control study using test-negative controls in
Spain, a VE of 90% (95%CI: 48-100%) was found for
hospitalization with pH1N1; however, only 12/34 vacci-
nated participants received PandemrixW and 22 received
non-adjuvanted vaccines [21]. In contrast, in a Danish
register-based study of patients with underlying chronic
illness, the VE estimate 14 days after PandemrixW vaccin-
ation for the prevention of hospitalisation due to
pH1N1-infection was 44% (95% CI-19-73%) [28]. In a
number of studies in outpatients in general practice set-
tings [23-26,28-32], VE estimates ranged from 49% to
100%, the lowest estimate being among older patients
and those with underlying chronic conditions [28,30].
The only vaccine breakthroughs in our study were
observed in 2/3 vaccinated HIV-positive patients, sug-
gesting lower VE in this patient group. This is in line
with the reported lower immunogenicity of the AS03-
adjuvanted pH1N1-vaccine in HIV-infected persons
[33,34].
Limitations and strengths
The most serious limitation of our study was inadequate
power. Due to the early onset and rapid decline of the
pandemic wave, fewer patients than expected were
included. The participation of 59% among hospitalized
ARI-patients was also unexpectedly low, although
recruited and non-recruited patients were similar regard-
ing key demographic and clinical variables.
In addition, vaccination coverage among study partici-
pants was below our already pessimistic prognosis of 10%.
This reflected the low coverage attained in the Berlin
population of 6.8% (95%CI: 4.2–10.9%), only slightly better
in persons with higher vaccination priority (12.8%; 95%CI:
11.4–14.4%) [7,35]. There was controversial public discus-
sion in Germany, with 55% of participants in a representa-
tive telephone survey stating that information in the media
led to doubt regarding the advisability of pH1N1-vaccin-
ation [11].
A further weakness was our inability to verify the vaccin-
ation status in all cases, as a vaccination registry was not
Table 3 Comparison of ARI cases with matched hospital controls: analysis of vaccination status, underlying illness and
other potential risk factors
ARI cases vs. matched hospital
Variable Cases (151) Controls (246) MOR (95% CI) p
N % N %
Pandemic influenza vaccination 150 7 246 7 1.0 (0.4-2.5) 0.94
Seasonal influenza vaccination 2009/10 150 31 237 22 1.7 (1.1-2.8) 0.03
Seasonal influenza vaccination 2008/09 144 22 239 24 0.8 (0.4-1.5) 0.51
Seasonal influenza vaccination 2007/08 142 19 239 22 0.6 (0.4-1.7) 0.63
Pneumococcal vaccine 131 15 211 5 4.3 (1.5-11.8) 0.005
Pandemic influenza vaccine offered by employer 148 10 245 20 0.4 (0.2-0.8) 0.01
Any chronic underlying illness 152 67 246 57 4.5 (1.9-10.4 0.001
Any chronic lung disease 151 26 246 6 12.9 (4.5-36.4) <0.0001
COPD 150 16 246 10 1.9 (1.0-3.6) 0.05
Asthma 151 16 246 10 2.1 (1.0-4.3) 0.05
Chronic bronchitis 152 35 244 18 3.4 (1.9-6.1) <0.0001
Cardiovascular disease 152 39 245 30 1.9 (1.1-3.2) 0.02
Immunosuppression 146 15 246 0.4 35.2 (4.7-262.5) 0.001
BMI ≥31 151 21 244 24 0.9 (0.5-1.4) 0.54
Frailty 151 9 246 6 1.8 (0.8-4.0) 0.18
≥ 3 physician visits in past year 151 55 242 53 1.0 (0.7-1.6) 0.88
≥ 1 hospitalization in past year 152 30 245 34 0.9 (0.5-1.4) 0.57
Current smoker 152 44 246 47 0.9 (0.6-1.3) 0.53
>20 packyears vs. non-smoker 152 32 246 31 1.3 (0.7-2.3) 0.41
Alcohol: ≥ 1 drink/week 150 55 234 63 0.7 (0.4-1.0) 0.07
Children in household 152 38 246 19 2.7 (1.6-4.3) <0.0001
Public transport (>=3x/week) vs. none 152 41 244 44 0.9 (0.6-1.4) 0.52
Owns car 152 53 243 60 0.8 (0.5-1.1) 0.18
Completion of at least Grade 10 149 66 239 77 0.6 (0.4-0.9) 0.02
Private health insurance 152 15 244 19 0.6 (0.3-1.1) 0.11
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available. Vaccination status remained undocumented in a
high proportion of reportedly unvaccinated participants,
however, this proportion was similar in cases, matched
hospital and test-negative controls (Table 1). Several stud-
ies (reviewed in [36]) showed a high sensitivity (range 92–
100), but lower specificity (38-100%) of self-reported influ-
enza vaccination status in elderly persons. However, we
suspect that the validity of recall of pandemic vaccination
in adults ≤65 years may have been higher than for seasonal
vaccination due to the extensive media coverage of the
pandemic. Misclassification of vaccinated participants as
unvaccinated among cases would lead to overestimation
and among controls to underestimation of VE. In our
study, any likelihood of misclassification appears similar in
pH1N1 cases and their two control groups (Table 1).
Strengths of our study include the prospective recruit-
ment of cases and controls, the use of two control groups,
the exclusive use of a single pandemic vaccine, the use of
serology to confirm pH1N1-infections that would other-
wise not have been detected and the exclusion of controls
with anamnestic or serological evidence of previous
pH1N1-infection. Although we failed to obtain serum
samples in relatively high proportion of ARI cases with
negative (47/120; 39.2%) or – due to late testing – incon-
clusive (8/34; 23.5%) PCR results, results of patients who
did provide sera suggest that a maximum of 1 patient each
may have been wrongly classified as pH1N1-negative or as
having an unclear pH1N1 status (Figure 1) when in fact
pH1N1-positive: Of all 104 PCR negative patients with
serum available, only 1 had positive serology (1%), and of
the 26 patients with inconclusively negative PCR results
due to late swabbing with serum available, 3 were sero-
positive (11.5%).
Use of matched hospital and test-negative controls
Any control group should be representative of the popula-
tion from which cases originate and have a risk of exposure
to infection/vaccination similar to that of the cases [37-39].
Both our test-negative and community hospital controls ori-
ginated from the same population as test-positive cases.
Test-negative ARI patients had a similar risk of exposure to
respiratory infections, presumably including pH1N1, as
test-positive ARI cases. As we chose hospital controls with
acute diagnoses or minor elective procedures, we assumed
their potential risk of H1N1 exposure was also uninfluenced
by their impending hospitalisation. In addition, we matched
hospital controls according to date of admission and
adjusted the test-negative analysis by period of influenza cir-
culation. Furthermore, we matched hospital controls
according to their vaccination probability based on official
vaccination recommendations. Therefore, and because hos-
pital controls, test-negative controls and H1N1 cases were
similar with respect to frequency of smoking and social sta-
tus, we believe that both control groups were appropriately
selected for this study.
A comparison of the analyses using matched hospital
controls and test-negative controls in this study is limited
by the small numbers of recruited cases, vaccinated partici-
pants and lack of vaccination breakthroughs. The lower
proportion of vaccinated controls in the test-negative com-
parison led to a lower point estimate and wider, non-signifi-
cant 95%CI for the VE estimate than in the matched
analysis. Besides vaccination probability based on official
recommendations, an explanation for higher vaccination
coverage of hospital controls could be more frequent use of
out-patient health care resources. However, we found no
significant difference regarding the proportion with any or
>3 physician visits in the past year among hospital and
test-negative controls, respectively (see Table 2). The use of
pH1N1 test-negative ARI patients as controls has the prac-
tical advantage of eliminating the need for recruitment of
additional controls, and has been widely used in VE studies
performed in general practice sentinel networks [25,40].
The validity of this approach has been demonstrated, with a
risk of underestimation of VE when the diagnostic test has
low specificity or the ratio of influenza-confirmed to nega-
tive cases is low [41], as was the case in our study. On the
other hand, an advantage of using hospital rather than test-
negative controls is the ability to investigate potential risk
factors for pH1N1-infection other than vaccination. While
the comparison of pH1N1-positive cases with matched hos-
pital and test-negative controls gave broadly similar results
regarding pandemic vaccination, factors such as COPD, im-
munosuppression and contact to children in the household
were only identified as potential risk factors for pH1N1-
hospitalization when using matched hospital controls. This
is presumably because such factors increase the risk of ARI
regardless of aetiology, hence showing a similar distribution
among test-positive and test-negative ARI cases and con-
trols. Similarly, use of test-negative controls may result in
inherent matching on factors potentially related to vaccin-
ation, leading to a more conservative estimate of protective
effects, while, however, controlling for possible confounding
factors.
Table 4 pH1N1 vaccination status in HIV infected ARI
cases and controls













Vaccinated** 2 4 2 2 10
Not vaccinated 1 9 1 1 12
Unclear 0 0 0 1 1
Total 3 13 3 4 23
*Swabbed late and did not provide serum samples.
**Single dose of Pandemrix 28–110 days prior to symptom onset with
exception of one pH1N1-negative ARI case with 2 doses 119 and 91 days prior
to symptom onset.
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Seasonal influenza vaccination
We did not find evidence to suggest either increased or
decreased risk of pH1N1-infections in participants vacci-
nated with current or past seasonal influenza vaccines, al-
though the OR for seasonal vaccination in the two past
seasons were non-significantly elevated in the test-negative
comparison. Several Canadian studies using different study
designs found an increased risk of pH1N1 illness during
the initial pandemic wave in persons vaccinated with the
seasonal 2008/2009 influenza vaccine [42,43]. Other stud-
ies showed no association [21,23,25,44-47] or a protective
effect [48,49] of prior seasonal vaccination on pH1N1 ill-
ness. Besides possible biases or residual confounding, sev-
eral hypotheses were put forward to explain a possibly true
positive association [42,50-52].
Risk factors identified for hospitalization with pH1N1/ARI
Of possible risk factors for pH1N1 hospitalization identified
in our univariate matched analysis (Table 1), underlying re-
spiratory illness, immunosuppression, and obesity have also
been described by others as a risk factor for severe pH1N1-
infection [53-56]. Having been offered influenza vaccination
by one’s employer was inversely associated with pH1N1
hospitalization in univariate and with ARI in univariate and
multivariate matched analysis. We hypothesize that such an
offer may encourage higher awareness of infection risk or
simply reflect a “healthy worker” effect. Car ownership was
inversely and frequent use of public transport positively
associated with hospitalization due to pH1N1 but not ARI
in both the matched and the test-negative analyses. Car
ownership was associated with serologically confirmed sea-
sonal influenza in a cohort study of medical personnel, al-
though only in persons from households without children
[27]. We had too few pH1N1 cases to perform such a strati-
fied analysis. Since we excluded controls with evidence of
previous pH1N1-infection, acquired immunity through
increased exposure in public transport settings cannot ex-
plain this observed inverse association. A “healthy com-
muter” effect may be an explanation; but we did not see
such an association with ARI. The association of these two
variables with mobility and with exposure to children in the
household suggests that they were indirectly related to risk
of pH1N1 exposure.
We did not find a significant association between vari-
ous indicators of smoking and hospitalized pH1N1 ill-
ness or ARI, similar to many, but not all, other studies
(reviewed in [57]). The proportion of smokers in the
control groups (Table 2) was comparable to that in the
Berlin population aged 15–64 years in 2009 at 43% [58].
Why previous hospitalization should be inversely asso-
ciated with pH1N1-illness as observed in the matched
analysis is not entirely clear. It may have been associated
with a lower risk of pH1N1 exposure, e.g. through less
social interaction.
Pneumococcal and seasonal 2009/2010, but not
pH1N1 influenza vaccination were positively associated
with ARI in univariate but not multivariate analysis. As
shown by loss of statistical significance in multivariate
analysis, this was due to the higher proportion of persons
with an indication for these vaccines –such as COPD–
among ARI patients than controls (“confounding by indi-
cation”). Contact to children in the household was a risk
factor for hospitalization with ARI as well as pH1N1 ill-
ness, which is plausible as children have been shown to
play an important role in the transmission of influenza
and other viral respiratory illnesses to adults [59-62].
Conclusions
Despite several study limitations, our results suggest that
vaccination with the AS03-adjuvanted pH1N1-vaccine
was effective at preventing hospitalizations due to pan-
demic influenza in adults, in keeping with the limited
results seen in other hospital-based studies. To increase
the reliability of VE estimates and to permit stratified
analyses (e.g. VE for specific risk groups), results of stud-
ies assessing effectiveness of influenza vaccines for pre-
vention of severe disease from different centres could be
pooled to increase power, as currently performed within
I-MOVE (Influenza Monitoring Vaccine Effectiveness in
Europe) for the assessment of influenza VE in outpatient
sentinels [25]. The use of hospital but not test-negative
controls showed a statistically protective effect of
pH1N1-vaccination and permitted the integrated assess-
ment of risk factors for pH1N1-infection. Further studies
are warranted that compare the use and impact of differ-
ent control groups when assessing influenza VE in post-
marketing studies.
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